Binimetinib + Hydroxychloroquine for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the best dose of hydroxychloroquine combined with binimetinib for treating advanced pancreatic cancer with a KRAS mutation. Binimetinib stops cancer cells from growing, while hydroxychloroquine prevents them from protecting themselves. The goal is to find a more effective treatment for these patients.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, certain medications like digoxin, methotrexate, and some others are not allowed during the trial. It's best to discuss your current medications with the trial team to see if any adjustments are needed.
Is the combination of Binimetinib and Hydroxychloroquine safe for humans?
Binimetinib, when used in combination with other drugs, has been associated with serious side effects like peripheral neuropathies (nerve damage) and renal disorders (kidney problems). Hydroxychloroquine is generally considered safe but can have side effects like vision changes and heart issues. It's important to discuss potential risks with your doctor.12345
How is the drug combination of Binimetinib and Hydroxychloroquine unique for treating pancreatic cancer?
What data supports the effectiveness of the drug combination Binimetinib and Hydroxychloroquine for pancreatic cancer?
A case report showed that a patient with a difficult-to-treat type of colorectal cancer experienced a rapid improvement and a 17% reduction in tumor size within six weeks when treated with a combination of binimetinib, hydroxychloroquine, and another drug. This suggests potential effectiveness of the combination in similar cancers.110111213
Who Is on the Research Team?
Shubham Pant, MD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with metastatic pancreatic cancer that has a KRAS mutation. They must have had at least one prior treatment, be in good physical condition (ECOG 0 or 1), and meet certain blood criteria. Women of childbearing age need a negative pregnancy test and agree to use contraception, as do men.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive binimetinib and hydroxychloroquine orally twice daily on days 1-14, with cycles repeating every 14 days in the absence of disease progression or unacceptable toxicity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Binimetinib
- Hydroxychloroquine
Binimetinib is already approved in United States, European Union, Canada, Japan for the following indications:
- Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
- Unresectable or metastatic melanoma with a BRAF V600 mutation
- Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
- Unresectable or metastatic melanoma with a BRAF V600 mutation
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator